Fig. 4: Ratio of IFN-γ signature to IMS predicts response to ICI immunotherapy on the discovery cohort. | npj Genomic Medicine

Fig. 4: Ratio of IFN-γ signature to IMS predicts response to ICI immunotherapy on the discovery cohort.

From: Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Fig. 4

A–C ROC curve of sensitivity versus 1-specificity for the predictive performance of the IFN-γ/IMS ratio. The AUC values were 0.70 (95% CI: 0.50–0.90) for Hugo16, 0.83 (95% CI: 0.68–0.99) for Gide19, and 0.76 (95% CI: 0.59–0.94) for Riaz17. Patients with SD were not included in AUC calculation. D–F Comparison of the AUC of the IFN-γ/IMS ratio with nine GEP signatures in predicting response to ICI therapy from the literature: IFN-γ, Exp. Immu., Messina, IMPRES, T eff., Davoli, Cytolytic, Roh Immu., and Huang NRS. G–I Kaplan–Meier plots of OS segregated by IFN-γ/IMS with cutoff points selected according to the Youden index on individual cohorts.

Back to article page